Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 55 systematic review(s)/meta-analysis(es). ^[1-55]
• Nail Psoriasis Outcomes: Ixekizumab led to a 70.5% mean improvement in the Nail Psoriasis Severity Index (NAPSI) at 24 weeks, with 41% of patients reaching NAPSI 0. Compared to other treatments, Brodalumab (76.9%) and Etanercept (74%) showed higher mean NAPSI improvements, while Adalimumab had a higher proportion achieving NAPSI 0 at 44.6%.
• Psoriatic Arthritis (PsA) Response: Ixekizumab 80 mg administered either biweekly (Q2W) or every four weeks (Q4W) effectively reached ACR20 response rates in PsA patients. Among available treatments, Secukinumab 300 mg exhibited the highest American College of Rheumatology 20 (ACR20) response rate, with Ixekizumab Q2W following closely.
• Psoriasis Severity Improvement: Ixekizumab achieved high response rates for Psoriasis Area and Severity Index (PASI) 90 and PASI 100 in psoriasis patients, with effectiveness comparable to other Interleukin (IL)-17 inhibitors such as Secukinumab. Ixekizumab was notably more effective in reaching PASI 90 compared to Secukinumab.
• Axial Spondyloarthritis (axSpA) Scores: Significant improvements in axial spondyloarthritis metrics, including Assessment in SpondyloArthritis international Society 40% (ASAS40), Ankylosing Spondylitis Disease Activity Score (ASDAS), and Spondyloarthritis Research Consortium of Canada (SPARCC) scores, were observed with Ixekizumab, showing superior results compared to placebo and comparable efficacy to other IL-17 inhibitors.
• General Safety Profile: Ixekizumab presented no significant increase in serious adverse events (SAEs) compared to placebo; however, non-serious adverse events (NSAEs) were common, particularly injection site reactions. Ixekizumab's overall safety was similar to other IL-17 inhibitors, though NSAEs were more frequent than with placebo.
• Cardiovascular Safety: The incidence of major adverse cardiovascular events (MACEs) with Ixekizumab showed no significant difference from placebo, with a cardiovascular safety profile comparable to that of Secukinumab.
• Infectious Risks: Ixekizumab was associated with an increased risk of infections, including nasopharyngitis, at rates similar to other IL-17 inhibitors.
• Gastrointestinal Safety: The incidence of inflammatory bowel disease (IBD) and other gastrointestinal adverse events remained low with Ixekizumab, aligning with the rates observed in other IL-17 inhibitors.
• Skin of Color Populations and Biologic Naivety: Ixekizumab demonstrated consistent efficacy across skin of color (SOC) populations, with no significant differences in treatment outcomes noted across racial and ethnic backgrounds. Additionally, biologic-naive patients showed higher drug survival rates compared to biologic-experienced patients, indicating potentially better long-term adherence in biologic-naive populations.
• Elderly Patients and Patients with Prior Malignancy: Ixekizumab maintained similar efficacy in elderly patients as observed in younger populations, though with a higher incidence of serious adverse events in elderly users, requiring careful monitoring. For patients with a history of malignancy, no malignancy recurrence was reported, suggesting Ixekizumab’s safe use within this subgroup based on available data.